Drugs / PDI204
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06965751 | Jun 2025 → Jul 2026 overdue | COVID-19 | University of Melbourne | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDI204 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06965751 ↗ |
| Modality | Monoclonal antibody | “PDI204 is a fully human, immunoglobulin G1 (IgG1) monoclonal antibody (mAb)” NCT06965751 ↗ |
| Route | Intramuscular | “PDI204 via a single intravenous (IV) or intramuscular (IM) dose” NCT06965751 ↗ |
| Route | Intravenous | “PDI204 via a single intravenous (IV) or intramuscular (IM) dose” NCT06965751 ↗ |